NOGO-a neutralising immunoglobulin for treatment of...

Details NOGO-a neutralising immunoglobulin for treatment of... NOGO-a neutralising immunoglobulin for treatment of...

2011-08-02

2011-08-02

Spector, Lorraine (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S139100, C424S141100, C424S143100, C514S017700, C530S387100, C530S387300, C530S388200, C530S389100

Reexamination Certificate

active

07988964

ABSTRACT:
The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases.

REFERENCES:
patent: 6420388 (2002-07-01), Emonds-Alt et al.
patent: WO 95/32948 (1995-12-01), None
patent: WO 2004/052932 (2004-06-01), None
patent: WO 2005/014575 (2005-02-01), None
patent: WO 2005028508 (2005-03-01), None
patent: WO 2005/061544 (2005-07-01), None
patent: WO 2005/061545 (2005-07-01), None
Caroni et al., Neuron, 1(1):85-96, (1988).
Zander et al. Journal of Molecular Recognition, 20:185-196, May 2007.
Fiedler et al. Protein Engineering 15(11):931-941, Nov. 2002.
Rudikoff et al. Proc Natl Acad Sci USA, 1982 vol. 79.
MacCallum et al. J. Mol. Biol. (1996) 262, 732-745.
Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Vajdos et al. Journal of Molecular Biology. (2002) 320, 415-428.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Holm et al. Molecular Immunology, (2007) 44, 1075-1084.
Giardina, et al., “Discovery of a Novel Class of Selective Non-peptide Antagonists for the Human Neurokinin-3 Receptor. 2. Identification of (S)-N-(1-Phenylpropy1)-3Hydroxy-2-Phenylquinoli NE-4-Carboxamide (SB 223412),”Journal of Medicinal Chemistry,vol. 42, No. 6, pp. 1053-1065 (1999).
Pemberton, et al., “Effects of a NK-3 Receptor Antagonist on ICV Administered Senktide—Induced Behaviours in the Guinea Pig,”Society for Neuroscience Abstract Viewer and Itinerary Planner,vol. 2003, abstract No. 858.6 (2003).
Glick, et al., “Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia,”Annals of Internal Medicine,vol. 134, No. 1, pp. 47-60 (2001).
Bandtlow, et al., European Journal of Biochemistry, vol. 241, No. 2, pp. 468-475, 1996.
Bareyre, et al., The Journal of Neuroscience, vol. 22, No. 16, pp. 7097-7110, Aug. 15, 2002.
Brosamle, et al., The Journal of Neuroscience, vol. 20, No. 21, pp. 8061-8068, Nov. 1, 2000.
Emerick, et al., The Journal of Neuroscience, vol. 23, No. 12, pp. 4826-4830 Jun. 2003.
Karim, et al., Brain Research Reviews, vol. 36, pp. 204-212, 2001.
Papadopoulos, et al., Ann. Neurol. vol. 51, pp. 433-441, 2002.
Reindl, et al., Journal of Neuroimmunology, vol. 145., No. 1, pp. 139-147, 2003.
Schmidlin, et al., Program No. 275.9. 2003 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2003. Online.
Schnell, et al., Program No. 678.9. 2003 Abstract Viewer/Itinerary Planner. Washington DC: Society for Neuroscience, 2003. Online.
Schwab, et al., Program No. 678.5. 2003 Abstract Viewer/Itinerary Planner. Washington DC: Society for Neuroscience, 2003. Online.
Wiessner, et al., Journal of Cerebral Blood Flow & Metabolism, vol. 23, pp. 154-165, 2003.

Affiliated with

Also associated with

Rating

NOGO-a neutralising immunoglobulin for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with NOGO-a neutralising immunoglobulin for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NOGO-a neutralising immunoglobulin for treatment of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2679490